Aaron Michael Kinney, MD
Family Practice · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · Sutter Valley Medical Foundation
Looking this up.
Hospitals listed: Sutter Medical Center, Sacramento. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kinney’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$23,185
Medicare paid this office $23,185 for 199 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 134 | $11,562 | $85 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 16 | $2,236 | $140 |
| Long return visit (40+ min) | 15 | $2,084 | $139 |
| Short return visit (20+ min) | 30 | $1,850 | $62 |
| New patient visit (45+ min) | 15 | $1,240 | $83 |
See all 10 services
| Return visit (30+ min) | 134 | $11,562 | $85 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 16 | $2,236 | $140 |
| Long return visit (40+ min) | 15 | $2,084 | $139 |
| Short return visit (20+ min) | 30 | $1,850 | $62 |
| New patient visit (45+ min) | 15 | $1,240 | $83 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 17 | $855 | $50 |
| Detection test by immunoassay with direct visual observation for influenza virus | 11 | $178 | $16 |
| Injection of drug or substance under skin or into muscle | 11 | $136 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 12 | $134 | $11 |
| Automated urinalysis test | 35 | $81 | $2 |
Procedures Medicare counted
| Removal of nail tissue | 1-10 | None |
| Removal of tissue | 1-10 | None |
Who their Medicare patients are
199 Original Medicare patients in 2024. Average age 75 · Under 65 11% · 85 and older 15% · Women 63% · Also on Medicaid 20% · Health risk score 1.21. Above the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 70% · Chronic kidney disease 29% · Coronary heart disease 26% · Diabetes 24% · COPD 21% · Atrial fibrillation 21% · Depression 21% · Heart failure 17% · Cancer 15% · Stroke 7% · Dementia 6%.
The office billed $94,317, Medicare allowed $34,046 and paid $23,185; for 472 services of 43 kinds; $58 of it was for drugs given in the office and $23,127 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 199 | 472 | 75 | 1.21 | $94,317 | $23,185 |
| 2023 | 238 | 557 | 73 | 1.27 | $116,806 | $32,615 |
| 2022 | 266 | 524 | 72 | 1.14 | $117,861 | $33,647 |
| 2021 | 216 | 402 | 74 | 1.15 | $87,500 | $26,038 |
| 2020 | 234 | 388 | 72 | 1.12 | $82,172 | $20,611 |
| 2019 | 345 | 715 | 73 | 1.43 | $130,069 | $32,099 |
| 2018 | 383 | 860 | 72 | 1.31 | $138,058 | $33,610 |
| 2017 | 419 | 905 | 71 | 1.55 | $144,999 | $38,722 |
| 2016 | 110 | 246 | 70 | 1.48 | $41,542 | $11,521 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 125 | $12,319 | $95 |
| Long return visit (40+ min) | 45 | $5,762 | $128 |
| New patient visit (45+ min) | 26 | $3,174 | $122 |
| Short return visit (20+ min) | 33 | $2,391 | $72 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 13 | $1,817 | $140 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 32 | $1,609 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 28 | $334 | $12 |
| Injection of drug or substance under skin or into muscle | 17 | $196 | $12 |
| Automated urinalysis test | 51 | $112 | $2 |
2022: 10 services
| Return visit (30+ min) | 142 | $14,476 | $100 |
| Long return visit (40+ min) | 38 | $5,338 | $140 |
| New patient visit (45+ min) | 36 | $4,054 | $113 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 67 | $3,391 | $51 |
| Short return visit (20+ min) | 20 | $1,400 | $70 |
| New patient visit (30+ min) | 15 | $616 | $41 |
| Detection test by immunoassay with direct visual observation for influenza virus | 16 | $261 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 19 | $194 | $10 |
| Injection of drug or substance under skin or into muscle | 13 | $147 | $11 |
| Automated urinalysis test | 43 | $100 | $2 |
2021: 9 services
| Return visit (30+ min) | 101 | $10,258 | $99 |
| Long return visit (40+ min) | 29 | $4,414 | $147 |
| Short return visit (20+ min) | 48 | $3,571 | $74 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 33 | $1,693 | $51 |
| New patient visit (45+ min) | 14 | $1,596 | $114 |
| New patient visit (30+ min) | 18 | $1,454 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 29 | $366 | $13 |
| Injection of drug or substance under skin or into muscle | 12 | $134 | $11 |
| Automated urinalysis test | 35 | $85 | $2 |
2020: 7 services
| Return visit (30+ min) | 157 | $13,157 | $80 |
| Short return visit (20+ min) | 31 | $2,149 | $65 |
| Long return visit (40+ min) | 13 | $1,230 | $95 |
| New patient visit (15+ min) | 15 | $846 | $56 |
| New patient visit (30+ min) | 11 | $758 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 24 | $320 | $13 |
| Automated urinalysis test | 32 | $76 | $2 |
2019: 13 services
| Return visit (30+ min) | 239 | $20,106 | $79 |
| New patient visit (30+ min) | 27 | $2,199 | $81 |
| Short return visit (20+ min) | 29 | $1,670 | $58 |
| Long return visit (40+ min) | 17 | $1,647 | $97 |
| New patient visit (15+ min) | 18 | $904 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 43 | $567 | $13 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 33 | $458 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 36 | $305 | $8 |
| Inhalation treatment for airway obstruction or sputum production | 20 | $302 | $14 |
| Injection of drug or substance under skin or into muscle | 11 | $143 | $13 |
| Automated urinalysis test | 52 | $132 | $2 |
| Insertion of needle into vein for collection of blood sample | 32 | $97 | $3 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 13 | $1 | None |
2018: 14 services
| Return visit (30+ min) | 281 | $22,393 | $76 |
| Short return visit (20+ min) | 47 | $2,427 | $51 |
| New patient visit (30+ min) | 37 | $2,280 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 45 | $592 | $13 |
| Injection of drug or substance under skin or into muscle | 20 | $329 | $16 |
| Inhalation treatment for airway obstruction or sputum production | 26 | $322 | $12 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 23 | $310 | $13 |
| Detection test by immunoassay with direct visual observation for influenza virus | 19 | $308 | $16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 25 | $235 | $9 |
| Automated urinalysis test | 57 | $160 | $3 |
| Insertion of needle into vein for collection of blood sample | 36 | $106 | $3 |
| Blood count, hemoglobin | 16 | $46 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 12 | $15 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 23 | $2 | None |
2017: 14 services
| Return visit (30+ min) | 250 | $22,499 | $84 |
| Short return visit (20+ min) | 102 | $5,469 | $51 |
| New patient visit (30+ min) | 40 | $2,963 | $74 |
| New patient visit (15+ min) | 23 | $843 | $37 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 53 | $727 | $13 |
| Injection of drug or substance under skin or into muscle | 25 | $558 | $21 |
| Inhalation treatment for airway obstruction or sputum production | 24 | $374 | $16 |
| Automated urinalysis test | 88 | $280 | $3 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 12 | $150 | $12 |
| Blood count, hemoglobin | 19 | $60 | $3 |
| Insertion of needle into vein for collection of blood sample | 20 | $59 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 16 | $50 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 17 | $34 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 11 | $1 | None |
2016: 4 services
| Short return visit (20+ min) | 59 | $3,746 | $54 |
| Return visit (30+ min) | 38 | $3,210 | $82 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | $155 | $12 |
| Automated urinalysis test | 19 | $69 | $3 |
Medicaid work
$4,592 in 2024
Medicaid paid $4,592 for 58 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 58 | $4,592 |
| 2024 | 58 | 1 | 16 | $4,592 |
| 2023 | 145 | 2 | 26 | $6,745 |
| 2021 | 12 | 1 | 12 | $834 |
| 2020 | 12 | 1 | 12 | $449 |
| 2019 | 60 | 1 | 17 | $3,023 |
| 2018 | 226 | 3 | 21 | $12,501 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 101 | $4,021 |
| Return visit (30+ min) | 44 | $2,724 |
2021
| Return visit (30+ min) | 12 | $834 |
2020
| Return visit (30+ min) | 12 | $449 |
2019
| Return visit (30+ min) | 60 | $3,023 |
2018
| Return visit (30+ min) | 200 | $11,845 |
| Short return visit (20+ min) | 14 | $453 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 12 | $203 |
Drugs they prescribed that Part D paid
$8,625
Pharmacies billed $8,625 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
229 generic and fewer than 11 brand-name prescriptions · $8,625 in drug cost · 127 antibiotic prescriptions to 104 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Doxycycline Monohydrate | 30 | $222 | $7 |
| Amoxicillin-Clavulanate Potass | 22 | $148 | $7 |
| Amoxicillin | 19 | $119 | $6 |
| Cephalexin | 24 | $110 | $5 |
| Mupirocin | 12 | $101 | $8 |
See all 6 drugs
| Doxycycline Monohydrate | 30 | $222 | $7 |
| Amoxicillin-Clavulanate Potass | 22 | $148 | $7 |
| Amoxicillin | 19 | $119 | $6 |
| Cephalexin | 24 | $110 | $5 |
| Mupirocin | 12 | $101 | $8 |
| Prednisone | 13 | $34 | $3 |
Year by year
| 2024 | 252 | 177 | None | None | $8,625 |
| 2023 | 305 | 205 | 0% (0) | 6% | $9,245 |
| 2022 | 290 | 210 | None | 4% | $6,185 |
| 2021 | 157 | 119 | 0% (0) | 10% | $3,528 |
| 2020 | 170 | 121 | 0% (0) | 14% | $3,977 |
| 2019 | 272 | 198 | 0% (0) | 21% | $9,311 |
| 2018 | 294 | 203 | None | 12% | $6,700 |
| 2017 | 448 | 259 | 3% (14) | 16% | $19,434 |
| 2016 | 368 | 115 | 8% (31) | None | $19,854 |
| 2015 | 70 | 29 | None | 17% | $3,278 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Doxycycline Monohydrate | 35 | $369 | $11 |
| Cephalexin | 30 | $176 | $6 |
| Cefdinir | 13 | $158 | $12 |
| Paxlovid (Eua) | 13 | $128 | $10 |
| Amoxicillin | 25 | $127 | $5 |
| Prednisone | 23 | $76 | $3 |
| Sulfamethoxazole-Trimethoprim | 12 | $55 | $5 |
2022: 7 drugs
| Cephalexin | 49 | $360 | $7 |
| Doxycycline Monohydrate | 31 | $313 | $10 |
| Mupirocin | 15 | $225 | $15 |
| Paxlovid (Eua) | 17 | $183 | $11 |
| Amoxicillin-Clavulanate Potass | 14 | $150 | $11 |
| Naproxen | 21 | $86 | $4 |
| Prednisone | 13 | $37 | $3 |
2021: 3 drugs
| Cefdinir | 12 | $239 | $20 |
| Doxycycline Monohydrate | 14 | $187 | $13 |
| Cephalexin | 26 | $138 | $5 |
2020: 2 drugs
| Doxycycline Monohydrate | 25 | $322 | $13 |
| Cephalexin | 15 | $81 | $5 |
2019: 5 drugs
| Cefdinir | 23 | $438 | $19 |
| Cephalexin | 32 | $201 | $6 |
| Doxycycline Monohydrate | 24 | $185 | $8 |
| Naproxen | 15 | $52 | $3 |
| Prednisone | 19 | $45 | $2 |
2018: 6 drugs
| Cephalexin | 43 | $199 | $5 |
| Azithromycin | 33 | $185 | $6 |
| Doxycycline Monohydrate | 13 | $98 | $8 |
| Sulfamethoxazole-Trimethoprim | 12 | $51 | $4 |
| Prednisone | 17 | $43 | $3 |
| Amoxicillin | 11 | $32 | $3 |
2017: 11 drugs
| Ventolin Hfa | 11 | $588 | $53 |
| Atorvastatin | 19 | $317 | $17 |
| Cephalexin | 40 | $232 | $6 |
| Azithromycin | 28 | $143 | $5 |
| Lisinopril | 14 | $124 | $9 |
| Doxycycline Monohydrate | 11 | $123 | $11 |
| Amoxicillin-Clavulanate Potass | 13 | $116 | $9 |
| Ciprofloxacin | 14 | $93 | $7 |
| Prednisone | 18 | $55 | $3 |
| Losartan | 11 | $35 | $3 |
| Ibuprofen | 11 | $34 | $3 |
2016: 5 drugs
| Hydrocodone-Acetaminophen | 19 | $239 | $13 |
| Atorvastatin | 20 | $238 | $12 |
| Lisinopril | 21 | $146 | $7 |
| Amlodipine Besylate | 24 | $83 | $3 |
| Clopidogrel | 12 | $66 | $6 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Randomized, Double Blind, Placebo Controlled, Phase 2 Study To Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild To Moderate Covid-19 Illness · 2021 | Their institution | $11,132 |
| Eli Lilly and Company · A Randomized, Double Blind, Placebo Controlled, Phase 2 Study To Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild To Moderate Covid-19 Illness · 2022 | Their institution | $10,000 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study To Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild To Moderate Covid-19 Illness (Blaze-4) · 2022 | Their institution | $10,000 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study To Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild To Moderate Covid-19 Illness (Blaze-4) · 2021 | This clinician | $6,511 |
Professional record
- NPI
- 1477996916
- Trained
- University of Vermont College of Medicine, 2013
- Group
- Sutter Bay Medical Foundation · Sutter Valley Medical Foundation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- Po Box 255228, Sacramento, CA, 95865
- NPI first listed
- 2013-04-15
- NPI last updated
- 2025-09-16
- NPI record certified
- 2025-09-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1201 Alhambra Blvd, Sacramento, CA, 95816